119 related articles for article (PubMed ID: 17627420)
1. Tumor dosimetry on SPECT (186)Re-HEDP scans: variations in the results from the reconstruction methods used.
Divoli A; Bloch G; Chittenden S; Malaroda A; O'Sullivan JM; Dearnaley DP; Flux GD
Cancer Biother Radiopharm; 2007 Feb; 22(1):121-4. PubMed ID: 17627420
[TBL] [Abstract][Full Text] [Related]
2. Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
Denis-Bacelar AM; Chittenden SJ; McCready VR; Divoli A; Dearnaley DP; O'Sullivan JM; Johnson B; Flux GD
Br J Radiol; 2018 Apr; 91(1084):20170795. PubMed ID: 29293372
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trials of
Denis-Bacelar AM; Chittenden SJ; Dearnaley DP; Divoli A; O'Sullivan JM; McCready VR; Johnson B; Du Y; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):620-629. PubMed ID: 27770145
[TBL] [Abstract][Full Text] [Related]
5. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Lam MG; Bosma TB; van Rijk PP; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1425-33. PubMed ID: 19319526
[TBL] [Abstract][Full Text] [Related]
6. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
[TBL] [Abstract][Full Text] [Related]
7. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate.
Israel O; Keidar Z; Rubinov R; Iosilevski G; Frenkel A; Kuten A; Betman L; Kolodny GM; Yarnitsky D; Front D
J Clin Oncol; 2000 Jul; 18(14):2747-54. PubMed ID: 10894875
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
9. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A
Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases.
Palmedo H; Guhlke S; Bender H; Sartor J; Schoeneich G; Risse J; Grünwald F; Knapp FF; Biersack HJ
Eur J Nucl Med; 2000 Feb; 27(2):123-30. PubMed ID: 10755716
[TBL] [Abstract][Full Text] [Related]
11. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma.
Syed R; Bomanji J; Nagabhushan N; Kayani I; Groves A; Waddington W; Cassoni A; Ell PJ
J Nucl Med; 2006 Dec; 47(12):1927-35. PubMed ID: 17138735
[TBL] [Abstract][Full Text] [Related]
12. Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
Koutsikos J; Leondi A
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1392-3; author reply 1394-5. PubMed ID: 18438661
[No Abstract] [Full Text] [Related]
13. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
Liepe K; Franke WG; Kropp J; Koch R; Runge R; Hliscs R
Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
[TBL] [Abstract][Full Text] [Related]
14. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
Liepe K; Geidel HH; Bergmann R; Haase M; Runge R; Kotzerke J
Nucl Med Commun; 2009 Sep; 30(9):693-9. PubMed ID: 19528873
[TBL] [Abstract][Full Text] [Related]
15. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Palmedo H; Bender H; Schomburg A; Grünwald F; Schöneich G; Zamorra P; Reichmann K; Dierke-Dzierzon C; Mallmann P; Biersack HJ
Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
[TBL] [Abstract][Full Text] [Related]
16. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.
Limouris G; Shukla SK; Manetou A; Kouvaris I; Plataniotis G; Triantafyllou N; Rigas AV; Vlahos L
Anticancer Res; 1997; 17(3B):1699-704. PubMed ID: 9179222
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
18. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
[TBL] [Abstract][Full Text] [Related]
19. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
20. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
